Study guide
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations
Key Takeaways Explain This Topic AI
Under BTS/NICE/SIGN NG245 (2024), adult asthma is confirmed by a raised blood eosinophil count or FeNO of 50 ppb or more, then by bronchodilator reversibility (FEV1 up 12% and 200 mL), PEF variability of 20% or more, or bronchial challenge.
From age 12, NG245 starts treatment with as-needed low-dose ICS/formoterol (AIR therapy), then low-dose MART, then moderate-dose MART; SABA-only treatment is no longer used, and LTRA or LAMA trials precede specialist referral.
Acute asthma exacerbations are graded into moderate (PEF 50-75%), severe (PEF 33-50%, RR >= 25, HR >= 110, incomplete sentences), and life-threatening (PEF < 33%, SpO2 < 92%, silent chest, cyanosis, bradycardia, confusion, exhaustion, normal or elevated PaCO2).
Immediate emergency treatment of acute severe asthma combines high-flow oxygen (target SpO2 94-98%), oxygen-driven nebulised salbutamol 5 mg and ipratropium 0.5 mg, systemic corticosteroids (prednisolone 40-50 mg or IV hydrocortisone 100 mg), and IV magnesium sulphate 1.2-2 g for refractory cases.
A normal PaCO2 (4.5-6.0 kPa) in a tachypnoeic, severe asthmatic is an ominous sign indicating diaphragmatic exhaustion and impending respiratory arrest, requiring immediate senior anaesthetic and intensive care consultation for mechanical ventilation.
Last updated: October 2026
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations
Asthma is a chronic inflammatory disorder of the conducting airways characterized by bronchial hyperresponsiveness, reversible airflow limitation, and airway remodeling. In clinical practice and UK licensing examinations, mastery of objective diagnostic thresholds, stepwise maintenance titration, and structured emergency resuscitation is essential.
1. Pathophysiology and Clinical Presentation
The hallmark of asthma is chronic eosinophilic or non-eosinophilic airway inflammation mediated by T-helper 2 (Th2) lymphocytes, interleukin cytokines (IL-4, IL-5, IL-13), and mast cell degranulation. Release of histamine, leukotrienes, and prostaglandins produces smooth muscle bronchospasm, mucosal oedema, and hypersecretion of thick, tenacious mucus.
Typical Clinical Features
Patients typically present with variable and episodic respiratory symptoms that fluctuate over time and intensity:
Wheezing: Expiratory, high-pitched, polyphonic wheezing across bilateral lung zones.
Breathlessness and Chest Tightness: Often worse in the early morning, during nocturnal waking, or following physical exertion.
Dry Cough: Frequently nocturnal or precipitated by cold air, aerosol irritants, viral upper respiratory tract infections, and exercise.
Personal or Family Atopy: Strong association with allergic rhinitis, atopic eczema, and seasonal pollen allergies.
Note
Isolated wheezing without episodic variation, or chronic productive purulent cough in smokers, should direct clinicians toward alternative diagnoses such as chronic obstructive pulmonary disease (COPD), bronchiectasis, foreign body aspiration, or heart failure.
2. Objective Diagnostic Pathway (BTS/NICE/SIGN NG245, 2024)
The joint British Thoracic Society, NICE and SIGN guideline NG245 ( Asthma: diagnosis, monitoring and chronic asthma management , November 2024) replaced the separate NICE NG80 and BTS/SIGN pathways. Clinical diagnosis alone is not enough: objective tests are used in sequence. If a person is acutely unwell or highly symptomatic, treat them immediately and do whatever tests are available (for example eosinophil count, FeNO, or spirometry/PEF before and after a bronchodilator).
Adults (17 and Over)
Blood eosinophil count or FeNO first: diagnose asthma if the eosinophil count is above the laboratory reference range or the FeNO level is 50 ppb or more . FeNO measures eosinophilic airway inflammation (nitric oxide from inducible nitric oxide synthase in the bronchial epithelium).
Bronchodilator reversibility (BDR) with spirometry if not confirmed: diagnose asthma if FEV 1 \text{FEV}_1 FEV 1 rises by 12% or more AND 200 mL or more from the pre-bronchodilator value, or by 10% or more of the predicted normal FEV 1 \text{FEV}_1 FEV 1 . Spirometry often shows obstruction ( FEV 1 / FVC \text{FEV}_1/\text{FVC} FEV 1 / FVC below the lower limit of normal or 0.70), but normal spirometry between attacks does not exclude asthma.
Peak expiratory flow (PEF) variability if spirometry is unavailable or delayed: measure PEF twice daily for 2 weeks ; diagnose asthma if variability (amplitude percentage mean) is 20% or more .
Bronchial challenge test if asthma is still suspected clinically: refer for a test (for example methacholine, histamine or mannitol); bronchial hyper-responsiveness confirms asthma.
Children (5 to 16)
FeNO first: diagnose asthma if FeNO is 35 ppb or more .
BDR: an FEV 1 \text{FEV}_1 FEV 1 rise of 12% or more (or 10% or more of predicted) confirms asthma.
PEF variability: twice daily for 2 weeks; 20% or more is diagnostic.
Atopy and eosinophils: if still suspected, skin prick testing to house dust mite or total IgE, plus blood eosinophil count; diagnose if there is sensitisation or a raised IgE and eosinophils above 0.5 × 10 9 0.5 \times 10^9 0.5 × 1 0 9 /L. If doubt remains, refer to a paediatric specialist (including bronchial challenge).
Children under 5 cannot reliably do the tests: treat on clinical judgement as "suspected asthma" (for example an 8–12 week trial of paediatric low-dose ICS) and review.
Diagnostic Test Positive Threshold (Adults) Positive Threshold (Children 5–16)
Blood eosinophil count Above the laboratory reference range Used later, with atopy testing (above 0.5 × 10 9 0.5 \times 10^9 0.5 × 1 0 9 /L)
FeNO 50 ppb or more 35 ppb or more
Bronchodilator reversibility FEV 1 \text{FEV}_1 FEV 1 up 12% or more and 200 mL or more (or 10% of predicted) FEV 1 \text{FEV}_1 FEV 1 up 12% or more (or 10% of predicted)
- PEF variability 20% or more over 2 weeks 20% or more over 2 weeks
- Bronchial challenge Specialist test if still suspected Specialist test if still in doubt
- 3. Chronic Pharmacological Management (NG245)
The goal is control of symptoms, prevention of exacerbations and the lowest effective treatment. NG245 makes inhaled corticosteroid–formoterol (ICS/formoterol) combination inhalers the backbone of treatment from age 12 and ends SABA-only treatment .
People Aged 12 and Over
As-needed AIR therapy: newly diagnosed asthma starts with a low-dose ICS/formoterol inhaler taken as needed for symptom relief (anti-inflammatory reliever, "AIR"; in the UK, licensed products are budesonide/formoterol). Anyone with confirmed asthma using a SABA alone is switched to as-needed AIR.
Low-dose MART: if not controlled, use the same ICS/formoterol inhaler every day as maintenance and also as the reliever (maintenance and reliever therapy). Start directly at low-dose MART if the person is highly symptomatic (for example regular night waking) or presents with a severe exacerbation (with oral corticosteroids as needed).
Moderate-dose MART: if still not controlled.
Check FeNO and blood eosinophils: if either is raised, refer to a specialist in asthma care . If neither is raised, try a leukotriene receptor antagonist (LTRA, e.g. montelukast) or a long-acting muscarinic antagonist (LAMA) added to moderate-dose MART for 8–12 weeks , then keep, swap or add the other agent depending on response.
Specialist referral: asthma not controlled despite moderate-dose MART and trials of both an LTRA and a LAMA. Specialists consider biologics (omalizumab for severe allergic asthma; mepolizumab, benralizumab or reslizumab for severe eosinophilic asthma; dupilumab or tezepelumab) and, as a last resort, maintenance oral corticosteroids.
People already well controlled on regular ICS plus SABA, or ICS/LABA plus SABA, do not have to switch; NG245 says consider moving them to low- or moderate-dose MART if control is inadequate. People on MART do not normally need a separate SABA.
Children Aged 5 to 11
Twice-daily paediatric low-dose ICS with a SABA as needed.
If not controlled: paediatric low-dose MART if the child can manage the regimen; otherwise add an LTRA (8–12 week trial) or switch to a twice-daily paediatric low-dose ICS/LABA inhaler plus SABA.
Then paediatric moderate-dose MART (or moderate-dose ICS/LABA plus SABA).
Refer to a specialist in asthma care if still not controlled.
Important
Check Before Stepping Up: Before increasing treatment, check inhaler technique, adherence (prescription records), the diagnosis itself, and triggers such as smoking, damp or mould at home, air pollution, occupational exposures, NSAIDs and beta-blockers. Over-use of SABA (more than 2 inhalers a year) is a marker of poor control and high risk.
4. Acute Asthma Exacerbations: Clinical Severity Grading
An acute exacerbation is characterized by progressive breathlessness, cough, wheezing, and rapid reduction in PEF. Objective clinical triage using standardized British Thoracic Society (BTS/SIGN) criteria dictates the level of monitoring and immediate interventions required.
Severity Category Clinical Features Vital Signs & Spirometry Arterial Blood Gas (ABG)
Moderate Exacerbation Increasing symptoms; speech normal; no features of severe asthma PEF 50 – 75 % 50\text{--}75\% 50 – 75% best/predicted; RR < 25 /min \text{RR} < 25\text{/min} RR < 25 /min ; HR < 110 bpm \text{HR} < 110\text{ bpm} HR < 110 bpm ; SpO 2 ≥ 92 % \text{SpO}_2 \ge 92\% SpO 2 ≥ 92% Normal PaO 2 \text{PaO}_2 PaO 2 ; mild hypocapnia ( ↓ PaCO 2 \downarrow \text{PaCO}_2 ↓ PaCO 2 )
Severe Exacerbation Inability to complete full sentences in one breath; accessory muscle use PEF 33 – 50 % 33\text{--}50\% 33 – 50% best/predicted; RR ≥ 25 /min \text{RR} \ge 25\text{/min} RR ≥ 25 /min ; HR ≥ 110 bpm \text{HR} \ge 110\text{ bpm} HR ≥ 110 bpm ; SpO 2 ≥ 92 % \text{SpO}_2 \ge 92\% SpO 2 ≥ 92% PaO 2 > 8 kPa \text{PaO}_2 > 8\text{ kPa} PaO 2 > 8 kPa ; low PaCO 2 < 4.5 kPa \text{PaCO}_2 < 4.5\text{ kPa} PaCO 2 < 4.5 kPa (respiratory alkalosis)
Life-Threatening Exacerbation Silent chest (absent breath sounds); cyanosis; feeble respiratory effort; bradycardia or dysrhythmia; hypotension; exhaustion; confusion; coma PEF < 33 % < 33\% < 33% best/predicted; SpO 2 < 92 % \text{SpO}_2 < 92\% SpO 2 < 92% on ambient air Normal or elevated PaCO 2 \text{PaCO}_2 PaCO 2 ( ≥ 4.5 – 6.0 kPa \ge 4.5\text{--}6.0\text{ kPa} ≥ 4.5 – 6.0 kPa ); severe hypoxia ( PaO 2 < 8 kPa \text{PaO}_2 < 8\text{ kPa} PaO 2 < 8 kPa ); severe acidosis ( pH < 7.35 \text{pH} < 7.35 pH < 7.35 )
Near-Fatal Asthma Imminent respiratory arrest Unrecordable PEF; extreme bradypnoea; profound lethargy Rising PaCO 2 \text{PaCO}_2 PaCO 2 with rapidly declining arterial pH \text{pH} pH
The "Normal" PaCO2 Clinical Trap
During an acute asthma attack, hyperventilation driven by hypoxia and airway irritation typically blows off carbon dioxide, producing a low arterial PaCO 2 \text{PaCO}_2 PaCO 2 ( < 4.5 kPa < 4.5\text{ kPa} < 4.5 kPa ) and respiratory alkalosis.
Finding a "normal" PaCO 2 \text{PaCO}_2 PaCO 2 ( 4.5 – 6.0 kPa 4.5\text{--}6.0\text{ kPa} 4.5 – 6.0 kPa ) or elevated PaCO 2 \text{PaCO}_2 PaCO 2 ( > 6.0 kPa > 6.0\text{ kPa} > 6.0 kPa ) in an exhausted asthmatic indicates that the respiratory muscles have failed. The patient can no longer maintain minute ventilation. This constitutes an immediate life-threatening emergency signalling impending cardiorespiratory arrest.
5. Emergency Resuscitation Protocol
Emergency management follows the structured "O-S-H-I-M" protocol under continuous monitoring:
Oxygen Therapy:
Deliver high-flow humidified oxygen via a non-rebreathe reservoir bag mask.
Target Oxygen Saturation: 94 – 98 % 94\text{--}98\% 94 – 98% (unlike COPD, asthmatics are rarely at risk of hypercapnic oxygen suppression).
High-Dose Inhaled Bronchodilators (Salbutamol):
Salbutamol 5 mg 5\text{ mg} 5 mg nebulised, driven by 6 – 8 L/min 6\text{--}8\text{ L/min} 6 – 8 L/min of high-flow oxygen.
Repeat every 15 – 30 minutes 15\text{--}30\text{ minutes} 15 – 30 minutes , or administer continuous nebulisation ( 10 mg/hr 10\text{ mg/hr} 10 mg/hr ) for severe refractory obstruction.
Systemic Corticosteroids:
Oral prednisolone 40 – 50 mg 40\text{--}50\text{ mg} 40 – 50 mg once daily for at least 5 days (or until full recovery).
If the patient is vomiting, unconscious, or in severe distress, administer intravenous hydrocortisone 100 mg 100\text{ mg} 100 mg every 6 hours.
Inhaled Anticholinergics (Ipratropium Bromide):
Add nebulised ipratropium bromide 0.5 mg 0.5\text{ mg} 0.5 mg to salbutamol.
Administer every 4 – 6 hours 4\text{--}6\text{ hours} 4 – 6 hours in acute severe asthma, or every 20 minutes 20\text{ minutes} 20 minutes during the first hour of resuscitation in life-threatening presentations.
Intravenous Magnesium Sulphate:
Indicated for acute severe asthma unresponsive to initial nebulised therapy, or any life-threatening presentation.
Dose: Magnesium sulphate 1.2 – 2.0 g 1.2\text{--}2.0\text{ g} 1.2 – 2.0 g IV infused over 20 minutes.
Mechanism: Promotes bronchial smooth muscle relaxation by competing with calcium channels.
Second-Line Adjuncts (Under Senior Guidance):
Intravenous aminophylline loading dose ( 5 mg/kg 5\text{ mg/kg} 5 mg/kg over 30 minutes, omitted if on oral theophylline) followed by maintenance infusion.
Intravenous salbutamol infusion under telemetry monitoring.
Indications for Urgent Senior Anaesthetic / Intensive Care (ICU) Referral
Deteriorating or failing PEF despite maximal nebulisers.
Normal or rising PaCO 2 \text{PaCO}_2 PaCO 2 or severe metabolic/respiratory acidosis ( pH < 7.35 \text{pH} < 7.35 pH < 7.35 ).
Persistent or worsening hypoxaemia ( PaO 2 < 8.0 kPa \text{PaO}_2 < 8.0\text{ kPa} PaO 2 < 8.0 kPa ) despite maximal supplemental oxygen.
Signs of physical exhaustion, altered consciousness, confusion, or bradypnoea.
Cardiorespiratory arrest.
6. Discharge Criteria and Secondary Prevention
Patients may be considered for discharge when clinically stable on their discharge regimen for at least 12–24 hours:
Peak expiratory flow > 75 % > 75\% > 75% of personal best or predicted.
Inhaler technique observed and confirmed correct with a spacer.
Completed minimum 5-day course of oral prednisolone ( 40 – 50 mg 40\text{--}50\text{ mg} 40 – 50 mg daily).
Review and update of a personalized Written Asthma Action Plan (WAAP) .
General practice follow-up arranged within 48 hours of discharge.
Specialist respiratory outpatient clinic follow-up within 4 weeks for all admissions.